Compare Merck & Co., Inc. (MRK) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Advanced Drainage Systems Inc — how do they compare? Merck & Co., Inc. trades at $133.55 (market cap $321.77B), while Advanced Drainage Systems Inc trades at $143.7 (market cap $10.83B). The key difference: Merck & Co., Inc. is far larger — about 29.7× Advanced Drainage Systems Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | WMS | |
|---|---|---|
Market Cap | $321.77B | $10.83B |
Sector | Health | Industrials |
52-Week High | $131.84 | $175.38 |
52-Week Low | $77.60 | $129.50 |
Enterprise Value | $368.53B | $12.44B |
Dividend Yield | 2.61% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
WMS trades at $140.22, down 1.02% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin. Recent news highlights Q1 2027 revenue growth of 21% year-over-year and a quarterly dividend declaration.
The outlook is mixed: analyst consensus is a Buy with a $185.86 price target, implying upside, but technical weakness and a Zacks Strong Sell rating (June 22, 2026) pose near-term risks. Investment appeal hinges on execution of growth initiatives amid competitive pressures and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
